<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETRIUMÂ - progesteroneÂ capsuleÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>500032 Rev Jan 2008</p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<a href="http://"></a>WARNINGS<p class="First">Progestins and estrogens should not be used for the prevention of 
cardiovascular disease. (See <span class="Bold"><a href="#section-8.1">WARNINGS, 
<span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></span>.)</p>
<p>The Women's Health Initiative (WHI) study reported increased risks of 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and 
<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5 
years of treatment with oral conjugated estrogens (CE 0.625Â mg) combined with 
medroxyprogesterone acetate (MPA 2.5Â mg) relative to placebo. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span>.)</p>
<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, 
reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 
65 years of age or older during 4 years of treatment with oral conjugated 
estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown 
whether this finding applies to younger postmenopausal women. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span>.)</p>
<p>Other doses of oral conjugated estrogens with medroxyprogesterone and other 
combinations and dosage forms of estrogens and progestins were not studied in 
the WHI clinical trials. In the absence of comparable data and product-specific 
studies, the relevance of the WHI findings to other products has not been 
established. Therefore, the risks should be assumed to be similar for all 
estrogen and progestin products. Because of these risks, estrogens with or 
without progestins should be prescribed at the lowest effective doses and for 
the shortest duration consistent with treatment goals and risks for the 
individual woman.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PROMETRIUMÂ® (progesterone, USP) Capsules contain micronized progesterone for 
oral administration. Progesterone has a molecular weight of 314.47 and a 
molecular formula of C<span class="Sub">21</span>H<span class="Sub">30</span>O<span class="Sub">2</span>. Progesterone (pregn-4-ene-3, 20-dione) is a white or creamy 
white, odorless, crystalline powder practically insoluble in water, soluble in 
alcohol, acetone and dioxane and sparingly soluble in vegetable oils, stable in 
air, melting between 126Â° and 131Â°C. The structural formula is:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf73c385-5173-4b54-af23-069581c5d560&amp;name=chemical%20structure.jpg"></p>
<p>Progesterone is synthesized from a starting material from a plant source and 
is chemically identical to progesterone of human ovarian origin. PROMETRIUM 
Capsules are available in multiple strengths to afford dosage flexibility for 
optimum management. PROMETRIUM Capsules contain 100 mg or 200 mg micronized 
progesterone.</p>
<p>The inactive ingredients for PROMETRIUM Capsules 100 mg include: peanut oil 
NF, gelatin NF, glycerin USP, lecithin NF, titanium dioxide USP, D&amp;C Yellow 
No. 10, and FD&amp;C Red No. 40.</p>
<p>The inactive ingredients for PROMETRIUM Capsules 200 mg include: peanut oil 
NF, gelatin NF, glycerin USP, lecithin NF, titanium dioxide USP, D&amp;C Yellow 
No. 10, and FD&amp;C Yellow No. 6.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">PROMETRIUM Capsules are an oral dosage form of micronized 
progesterone which is chemically identical to progesterone of ovarian origin. 
The oral bioavailability of progesterone is increased through 
micronization.</p>
<a href="http://"></a><a href="http://"></a>Pharmacokinetics<a href="http://"></a><p><span>Absorption:</span> After oral 
administration of progesterone as a micronized soft-gelatin capsule formulation, 
maximum serum concentrations were attained within 3 hours. The absolute 
bioavailability of micronized progesterone is not known. <a href="#t1">Table 
1</a> summarizes the mean pharmacokinetic parameters in postmenopausal women 
after five oral daily doses of PROMETRIUM Capsules 100 mg as a micronized 
soft-gelatin capsule formulation.</p>
<a href="http://"></a><a name="i99077466-9816-4874-88a9-cc449250025d"></a><table width="100%">
<caption><span>TABLE 1</span></caption>
<col align="left" width="25%">
<col align="left" width="25%">
<col align="left" width="25%">
<col align="left" width="25%">
<thead>
<tr class="First">
<td align="left"><span class="Bold">Parameter</span></td>
<td align="left"><span class="Bold">PROMETRIUM Capsules Daily Dose</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">100 
mg</span></td>
<td align="left"><span class="Bold">200 
mg</span></td>
<td align="left"><span class="Bold">300 
mg</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Cmax (ng/mL)</td>
<td align="left">17.3 Â± 21.9<span class="Sup">a</span>
</td>
<td align="left">38.1 Â± 37.8</td>
<td align="left">60.6 Â± 72.5</td>
</tr>
<tr>
<td align="left">Tmax (hr)</td>
<td align="left">1.5 Â± 0.8</td>
<td align="left">2.3 Â± 1.4</td>
<td align="left">1.7 Â± 0.6</td>
</tr>
<tr class="Last">
<td align="left">AUC (0-10) (ngâ€¢hr/mL)</td>
<td align="left">43.3 Â± 30.8</td>
<td align="left">101.2 Â± 66.0</td>
<td align="left">175.7 Â± 
170.3</td>
</tr>
</tbody>
</table>
<p>a Mean Â± S.D.</p>
<p> Serum progesterone concentrations appeared linear and dose proportional 
following multiple dose administration of PROMETRIUM Capsules 100 mg over the 
dose range 100 mg/day to 300 mg/day in postmenopausal women. Although doses 
greater than 300 mg/day were not studied in females, serum concentrations from a 
study in male volunteers appeared linear and dose proportional between 
100Â mg/day and 400 mg/day. The pharmacokinetic parameters in male volunteers 
were generally consistent with those seen in postmenopausal women.</p>
<a href="http://"></a><p><span>Distribution:</span> Progesterone is 
approximately 96% to 99% bound to serum proteins, primarily to serum albumin 
(50% to 54%) and transcortin (43% to 48%).</p>
<a href="http://"></a><p><span>Metabolism:</span> Progesterone is 
metabolized primarily by the liver largely to pregnanediols and pregnanolones. 
Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and 
sulfate metabolites. Progesterone metabolites which are excreted in the bile may 
be deconjugated and may be further metabolized in the gut via reduction, 
dehydroxylation, and epimerization.</p>
<a href="http://"></a><p><span>Excretion:</span> The glucuronide and 
sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and 
urine. Progesterone metabolites which are excreted in the bile may undergo 
enterohepatic recycling or may be excreted in the feces.</p>
<a href="http://"></a><p><span>Special Populations:</span> The 
pharmacokinetics of PROMETRIUM Capsules have not been assessed in low body 
weight or obese patients.</p>
<a href="http://"></a><p><span>Race:</span> There is 
insufficient information available from trials conducted with PROMETRIUM 
Capsules to compare progesterone pharmacokinetics in different racial 
groups.</p>
<a href="http://"></a><p><span><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span> No 
formal studies have evaluated the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the disposition 
of progesterone. However, since progesterone is metabolized by the liver, use in 
patients with severe liver dysfunction or disease is contraindicated. (See <span class="Bold"><a href="#section-7">CONTRAINDICATIONS</a></span>.) If treatment with 
progesterone is indicated in patients with mild to moderate hepatic dysfunction, 
these patients should be monitored carefully.</p>
<a href="http://"></a><p><span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> No 
formal studies have evaluated the effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of 
progesterone. Since progesterone metabolites are eliminated mainly by the 
kidneys, PROMETRIUM Capsules should be used with caution and only with careful 
monitoring in patients with renal dysfunction. (See <span class="Bold"><a href="#section-9">PRECAUTIONS</a></span>.)</p>
<a href="http://"></a><p><span>Foodâ€“Drug Interaction:</span> 
Concomitant food ingestion increased the bioavailability of PROMETRIUM Capsules 
relative to a fasting state when administered to postmenopausal women at a dose 
of 200 mg.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<p class="First"><span>Drugâ€“Drug Interaction:</span> The 
metabolism of progesterone by human liver microsomes was inhibited by 
ketoconazole (IC<span class="Sub">50</span> less than 0.1 Î¼M). Ketoconazole is a known 
inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or 
other known inhibitors of this enzyme may increase the bioavailability of 
progesterone. The clinical relevance of the <span class="Italics">in vitro</span> 
findings is unknown.</p>
<p>Coadministration of conjugated estrogens and PROMETRIUM Capsules to 29 
postmenopausal women over a 12-day period resulted in an increase in total 
estrone concentrations (Cmax 3.68 ng/mL to 4.93 ng/mL) and total equilin 
concentrations (Cmax 2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17Î² 
estradiol concentrations (Cmax 0.037 ng/mL to 0.030 ng/mL). The half-life of the 
conjugated estrogens was similar with coadministration of PROMETRIUM Capsules. 
<a href="#t2">Table 2</a> summarizes the pharmacokinetic parameters.</p>
<a href="http://"></a><a name="i0cbf4059-7a7f-4b14-89d9-7738e7fb291b"></a><table width="100%">
<caption><span>TABLE 2 Mean (Â± S.D.) Pharmacokinetic Parameters for Estradiol, 
Estrone, and Equilin Following Coadministration of Conjugated Estrogens 0.625 mg 
and PROMETRIUM Capsules 200Â mg for 12 Days to Postmenopausal Women</span></caption>
<col align="left" width="14%">
<col align="left" width="11%">
<col align="left" width="8%">
<col align="left" width="18%">
<col align="left" width="14%">
<col align="left" width="13%">
<col align="left" width="18%">
<thead>
<tr class="First">
<td align="left">
<br>Â </td>
<td align="left"><span class="Bold">Conjugated Estrogens</span></td>
<td align="left"><span class="Bold">Conjugated Estrogens plus<br>PROMETRIUM Capsules</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">Drug</span></td>
<td align="left">
<span class="Bold">Cmax</span><br><span class="Bold">(ng/mL)</span>
</td>
<td align="left">
<span class="Bold">Tmax</span><br><span class="Bold">(hr)</span>
</td>
<td align="left">
<span class="Bold">AUC(0-24h)</span><br><span class="Bold">(ng</span>â€¢<span class="Bold">h/mL)</span>
</td>
<td align="left">
<span class="Bold">Cmax</span><br><span class="Bold">(ng/mL)</span>
</td>
<td align="left">
<span class="Bold">Tmax</span><br><span class="Bold">(hr)</span>
</td>
<td align="left">
<span class="Bold">AUC(0-24h)</span><br><span class="Bold">(ng</span>â€¢<span class="Bold">h/mL)</span>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Estradiol</td>
<td align="left">Â Â Â 0.037<br>Â± 0.048</td>
<td align="left">Â Â Â 12.7<br>Â± 9.1</td>
<td align="left">Â Â Â 0.676<br>Â± 0.737</td>
<td align="left">Â Â Â 0.030<br>Â± 0.032</td>
<td align="left">Â Â Â 17.32<br>Â± 1.21</td>
<td align="left">Â Â Â 0.561<br>Â± 0.572</td>
</tr>
<tr>
<td align="left">Estrone<br>Total<span class="Sup">a</span>
</td>
<td align="left">Â Â Â 3.68<br>Â± 1.55</td>
<td align="left">Â Â Â 10.6<br>Â± 6.8</td>
<td align="left">Â Â Â 61.3<br>Â± 26.36</td>
<td align="left">Â Â Â 4.93<br>Â± 2.07</td>
<td align="left">Â Â Â 7.5<br>Â± 3.8</td>
<td align="left">Â Â Â 85.9<br>Â± 41.2</td>
</tr>
<tr class="Last">
<td align="left">Equilin<br>Total<span class="Sup">a</span>
</td>
<td align="left">Â Â Â 2.27<br>Â± 0.95</td>
<td align="left">Â Â Â 6.0<br>Â± 4.0</td>
<td align="left">Â Â Â 28.8<br>Â± 13.0</td>
<td align="left">Â Â Â 3.22<br>Â± 1.13</td>
<td align="left">Â Â Â 5.3<br>Â± 2.6</td>
<td align="left">Â Â Â 38.1<br>Â± 20.2</td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> Total estrogens is the sume of conjugated and unconjugated estrogen.<br>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3.2"></a><p></p>
<a href="#section-"></a>Clinical Studies<a href="#section-"></a><p class="First"><span>Endometrial Protection</span>: In a 
randomized, double-blind clinical trial, 358 postmenopausal women, each with an 
intact uterus, received treatment for up to 36 months. The treatment groups 
were: PROMETRIUM Capsules at the dose of 200 mg/day for 12 days per 28-day cycle 
in combination with conjugated estrogens 0.625 mg/day (n=120); conjugated 
estrogens 0.625 mg/day only (n=119); or placebo (n=119). The subjects in all 
three treatment groups were primarily Caucasian women (87% or more of each 
group). The results for the incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> in women 
receiving up to 3 years of treatment are shown in <a href="#section-"> Table 3</a>. A 
comparison of the PROMETRIUM Capsules plus conjugated estrogens treatment group 
to the conjugated estrogens only group showed a significantly lower rate of 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> (6% combination product vs. 64% estrogen alone) in the PROMETRIUM 
Capsules plus conjugated estrogens treatment group throughout 36 months of 
treatment.</p>
<a href="#section-"></a><a name="i0dc9821b-f234-4104-87cf-fef263e66993"></a><table width="100%">
<caption><span>TABLE 3 Incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span> in Women Receiving 3 Years 
of Treatment</span></caption>
<col align="left" width="40%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<thead>
<tr class="First">
<td align="left"><span class="Bold">Endometrial Diagnosis</span></td>
<td align="left"><br></td>
<td align="left"><span class="Bold">Treatment 
Group</span></td>
<td align="left"><br></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left">
<span class="Bold">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg</span><br><span class="Bold">(cyclical)</span>
</td>
<td align="left"><span class="Bold">Conjugated Estrogens 0.625 mg (only)</span></td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td align="left"><span class="Bold">% 
of<br>patients</span></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td align="left"><span class="Bold">% 
of<br>patients</span></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td><span class="Bold">% 
of<br>patients</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">n=117</span></td>
<td align="left"><span class="Bold">n=115</span></td>
<td align="left"><span class="Bold">n=116</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">HYPERPLASIA</span><span class="Sup">a</span>
</td>
<td align="left">7</td>
<td align="left">6</td>
<td align="left">74</td>
<td align="left">64</td>
<td align="left">3</td>
<td>3</td>
</tr>
<tr>
<td align="left">Â Â Â Adenocarcinoma</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">1</td>
<td>1</td>
</tr>
<tr>
<td align="left">Â Â Â Atypical 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">14</td>
<td align="left">12</td>
<td align="left">0</td>
<td>0</td>
</tr>
<tr>
<td align="left">Â Â Â Complex 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">27</td>
<td align="left">23</td>
<td align="left">1</td>
<td>1</td>
</tr>
<tr class="Last">
<td align="left">Â Â Â Simple <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">6</td>
<td align="left">5</td>
<td align="left">33</td>
<td align="left">29</td>
<td align="left">1</td>
<td>1</td>
</tr>
</tbody>
</table>a Most advanced result to least advanced result:<br>Â  Adenocarcinoma &gt; atypical <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> &gt; complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> &gt; simple 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span><br><br>The times to diagnosis of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> over 36 months of treatment 
are shown in <a href="#section-"> Figure 1</a>. This figure illustrates 
graphically that the proportion of patients with <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was significantly 
greater for the conjugated estrogens group (64%) compared to the conjugated 
estrogens plus PROMETRIUM Capsules group (6%).<br><div class="Figure"><img alt="image of figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf73c385-5173-4b54-af23-069581c5d560&amp;name=figure%201.jpg"></div>
<br><span class="Bold">Figure 1 Time to <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span> in Women Receiving up to 36 Months of Treatment</span>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<p class="First">The discontinuation rates due to <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> over the 36 months of treatment 
are as shown in <a href="#t4">Table 4</a>. For any degree of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, the 
discontinuation rate for patients who received conjugated estrogens plus 
PROMETRIUM Capsules was similar to that of the placebo only group, while the 
discontinuation rate for patients who received conjugated estrogens alone was 
significantly higher. Women who permanently discontinued treatment due to 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> were similar in demographics to the overall study population.</p>
<a href="http://"></a><a name="i158dec80-421f-43c0-885f-d5dda99e8866"></a><table width="100%">
<caption><span>TABLE 4 Discontinuation Rate Due to <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span> Over 36 Months of 
Treatment</span></caption>
<col align="left" width="23%">
<col align="left" width="13%">
<col align="left" width="14%">
<col align="left" width="13%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="10%">
<thead>
<tr class="First">
<td align="left"><span class="Bold"><br>Most Advanced Biopsy Result Through 36 Months of 
Treatment</span></td>
<td align="left"><span class="Bold">Treatment Group</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">Conjugated Estrogens +<br>PROMETRIUM 
Capsules<br>(cyclical)</span></td>
<td align="left"><span class="Bold">Conjugated Estrogens<br>(only)</span></td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">n=120</span></td>
<td align="left"><span class="Bold">n=119</span></td>
<td align="left"><span class="Bold">n=119</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td align="left"><span class="Bold">% 
of<br>patients</span></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td align="left"><span class="Bold">% 
of<br>patients</span></td>
<td align="left"><span class="Bold">Number 
of<br>patients</span></td>
<td align="left"><span class="Bold">% 
of<br>patients</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Adenocarcinoma</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">1</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">Atypical <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">10</td>
<td align="left">8</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">Complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">21</td>
<td align="left">18</td>
<td align="left">1</td>
<td align="left">1</td>
</tr>
<tr class="Last">
<td align="left">Simple <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">13</td>
<td align="left">11</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
</tbody>
</table>
<p>In the same 3-year clinical trial, postmenopausal women were treated with 
PROMETRIUM Capsules in combination with conjugated estrogens, conjugated 
estrogens only, or placebo. There was no statistically significant difference 
between the PROMETRIUM Capsules plus conjugated estrogens group and the 
conjugated estrogens only group in increases of HDL-C and triglycerides, or in 
decreases of LDL-C. The changes observed in lipid profiles are shown in <a href="#t5">Table 5</a>.</p>
<a href="http://"></a><a name="i8474d0e0-8ba9-441b-865d-4c1eb1fce5c3"></a><table width="100%">
<caption><span>TABLE 5 Mean Changes from Baseline in Lipid Profiles After 36 Months of 
Treatment</span></caption>
<col align="left" width="30%">
<col align="left" width="11%">
<col align="left" width="11%">
<col align="left" width="11%">
<col align="left" width="11%">
<col align="left" width="11%">
<col align="left" width="11%">
<thead>
<tr class="First">
<td align="left"><span class="Bold">Parameter</span></td>
<td align="left">
<span class="Bold">Treatment Group</span><br><span class="Bold">Mean (Mean % 
Change)</span>
</td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left">
<span class="Bold">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg 
(cyclical)</span><span class="Sup">a</span>
</td>
<td align="left"><span class="Bold">Conjugated Estrogens 0.625 mg<br>(only)</span></td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">n= 176 to 177<span class="Sup">b</span></span></td>
<td align="left"><span class="Bold">n=171 to 173<span class="Sup">b</span></span></td>
<td align="left"><span class="Bold">n=171</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">Mean 
Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
<td align="left"><span class="Bold">Mean 
Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
<td align="left"><span class="Bold">Mean 
Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">LIPID PROFILE</td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
</tr>
<tr>
<td align="left">Â Â Â HDL-C(mmol/L)</td>
<td align="left">0.07</td>
<td align="left">5.1</td>
<td align="left">0.10</td>
<td align="left">7.2</td>
<td align="left">-0.05</td>
<td align="left">-2</td>
</tr>
<tr>
<td align="left">Â Â Â LDL-C(mmol/L)</td>
<td align="left">-0.43</td>
<td align="left">-11.8</td>
<td align="left">-0.36</td>
<td align="left">-9.5</td>
<td align="left">-0.14</td>
<td align="left">-2.9</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> 
(mmol/L)</td>
<td align="left">-0.26</td>
<td align="left">-4.0</td>
<td align="left">-0.22</td>
<td align="left">-3.6</td>
<td align="left">-0.15</td>
<td align="left">-1.8</td>
</tr>
<tr class="Last">
<td align="left">Â Â Â Triglyceride 
(mmol/L)<span class="Sup">c</span>
</td>
<td align="left">0.20</td>
<td align="left">17.8</td>
<td align="left">0.15</td>
<td align="left">13.7</td>
<td align="left">0.01</td>
<td align="left">0.6</td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> There are no significant changes (p less than 0.05) from conjugated estrogens values.<br><span class="Sup">b</span>Â  Number of subjects (n) varies by parameter.<br><span class="Sup">c</span>Â  Computed from log transformed data.<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<p class="First"><span class="Bold">Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></span>: In a single-center, 
randomized, double-blind clinical study that included premenopausal women with 
secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> for at least 90 days, administration of 10 days of 
PROMETRIUM Capsules therapy resulted in 80% of women experiencing withdrawal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> within 7 days of the last dose of PROMETRIUM Capsules, 300 mg/day 
(n=20), compared to 10% of women experiencing <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in the placebo 
group (n=21).</p>
<p>The rate of secretory transformation was evaluated in a multicenter, 
randomized, double-blind clinical study in estrogen-primed postmenopausal women. 
PROMETRIUM Capsules administered orally for 10 days at 400 mg/day (n=22) induced 
complete secretory changes in the endometrium in 45% of women compared to 0% in 
the placebo group (n=23).</p>
<a href="http://"></a><a href="http://"></a>Women's Health Initiative Studies<p>The Women's Health Initiative (WHI) enrolled a total of 27,000 
predominantly healthy postmenopausal women to assess the risks and benefits of 
either the use of oral 0.625 mg conjugated estrogens (CE) per day alone or the 
use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone 
acetate (MPA) per day compared to placebo in the prevention of certain chronic 
diseases. The primary endpoint was the incidence of coronary heart disease (CHD) 
(nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as 
the primary adverse outcome studied. A â€œglobal indexâ€? included the earliest 
occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), 
endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other 
cause. The study did not evaluate the effects of CE or CE/MPA on menopausal 
symptoms.</p>
<p>The CE/MPA substudy was stopped early because, according to the predefined 
stopping rule, the increased risk of breast cancer and cardiovascular events 
exceeded the specified benefits included in the â€œglobal index.â€? Results of the 
CE/MPA substudy, which included 16,608 women (average age of 63Â years, range 50 
to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average follow-up of 
5.2Â years are presented in <a href="#t6">Table 6</a> below.</p>
<a href="http://"></a><a name="i95a5ba8b-8ab2-4056-83c6-42c6e1e0ab5d"></a><table width="100%">
<caption><span>TABLE 6 Relative and Absolute Risk Seen in the CE/MPA Substudy of 
WHI<span class="Sup">a</span></span></caption>
<col align="left" width="42%">
<col align="left" width="20%">
<col align="left" width="18%">
<col align="left" width="18%">
<tbody class="Headless">
<tr class="First">
<td align="left"><span class="Bold">Event<span class="Sup">c</span></span></td>
<td align="left"><span class="Bold">Relative Risk<br>CE/MPA vs. placebo<br>at 5.2 Years<br>(95% 
CI*)</span></td>
<td align="left"><span class="Bold">Placebo<br>n = 8102</span></td>
<td align="left"><span class="Bold">CE/MPA<br>n = 8506</span></td>
</tr>
<tr><td align="left"><span class="Bold">Absolute Risk per<br>10,000 Women-years</span></td></tr>
<tr>
<td align="left">CHD events</td>
<td align="left">1.29 (1.02-1.63)</td>
<td align="left">30</td>
<td align="left">37</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="Italics">Non-fatal 
MI</span>
</td>
<td align="left"><span class="Italics">1.32 
(1.02-1.72)</span></td>
<td align="left"><span class="Italics">23</span></td>
<td align="left"><span class="Italics">30</span></td>
</tr>
<tr>
<td align="left">Â Â Â <span class="Italics">CHD 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td align="left"><span class="Italics">1.18 
(0.70-1.97)</span></td>
<td align="left"><span class="Italics">6</span></td>
<td align="left"><span class="Italics">7</span></td>
</tr>
<tr>
<td align="left">Invasive breast 
cancer<span class="Sup">b</span>
</td>
<td align="left">1.26 (1.00-1.59)</td>
<td align="left">30</td>
<td align="left">38</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="left">1.41 (1.07-1.85)</td>
<td align="left">21</td>
<td align="left">29</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td align="left">2.13 (1.39-3.25)</td>
<td align="left">8</td>
<td align="left">16</td>
</tr>
<tr>
<td align="left">Colorectal cancer</td>
<td align="left">0.63 (0.43-0.92)</td>
<td align="left">16</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left">Endometrial cancer</td>
<td align="left">0.83 (0.47-1.47)</td>
<td align="left">6</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td align="left">0.66 (0.45-0.98)</td>
<td align="left">15</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to causes other 
than the events above</td>
<td align="left">0.92 (0.74-1.14)</td>
<td align="left">40</td>
<td align="left">37</td>
</tr>
<tr>
<td align="left">Global Index <span class="Sup">c</span>
</td>
<td align="left">1.15 (1.03-1.28)</td>
<td align="left">151</td>
<td align="left">170</td>
</tr>
<tr><td align="left">Â </td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> <span class="Sup">d</span>
</td>
<td align="left">2.07 (1.49-2.87)</td>
<td align="left">13</td>
<td align="left">26</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> <span class="Sup">d</span>
</td>
<td align="left">0.66 (0.44-0.98)</td>
<td align="left">15</td>
<td align="left">9</td>
</tr>
<tr class="Last">
<td align="left">Other osteoporotic 
<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> <span class="Sup">d</span>
</td>
<td align="left">0.77 (0.69-0.86)</td>
<td align="left">170</td>
<td align="left">131</td>
</tr>
</tbody>
</table>
<span class="Sup">a</span>Â  adapted from <span class="Italics">JAMA</span>, 2002; 288:321-333<br><span class="Sup">b</span>Â  includes metastatic and non-metastatic breast cancer with the exception of <span class="Italics">in situ</span> breast cancer<br><span class="Sup">c</span>Â  a subset of the events was combined in a â€œglobal index,â€? defined as the earliest 
occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, 
endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other 
causes<br><span class="Sup">d</span>Â  not included in Global Index<br>*Â  nominal confidence intervals unadjusted for multiple looks and multiple comparisons</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<p class="First">For those outcomes included in the "global index," the absolute excess risks 
per 10,000 women-years in the group treated with CE/MPA were 7 more CHD events, 
8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 8 more PEs, and 8 more invasive breast cancers, while the 
absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers 
and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the 
â€œglobal indexâ€? was 19 per 10,000 women-years. There was no difference between 
the groups in terms of all-cause mortality. (See <span class="Bold"><a href="#section-3">BOXED WARNINGS</a>, <a href="#section-8">WARNINGS</a></span>, 
and <span class="Bold"><a href="#section-9">PRECAUTIONS</a></span>.)</p>
<a href="http://"></a><a href="http://"></a>Women's Health Initiative Memory Study<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of 
WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age 
and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 
years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated 
estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen/progestin 
group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 
women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) 
compared to placebo. Differences between groups became apparent in the first 
year of treatment. It is unknown whether these findings apply to younger 
postmenopausal women. (See <span class="Bold"><a href="#section-3">BOXED 
WARNINGS</a> and <a href="#section-8.4">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PROMETRIUM Capsules are indicated for use in the prevention of endometrial 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in nonhysterectomized postmenopausal women who are receiving 
conjugated estrogens tablets. They are also indicated for use in secondary 
<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PROMETRIUM Capsules should not be used in women with any of the 
following conditions:</p>
<ol>
<li><span class="Bold">PROMETRIUM Capsules should not be used in patients with 
known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to its ingredients. PROMETRIUM Capsules contain peanut 
oil and should never be used by patients allergic to peanuts.</span></li>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known, suspected, or history of cancer of the breast.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these 
conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic 
disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>Known or suspected pregnancy. There is no indication for PROMETRIUM Capsules 
in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> 
in children born to women who have used estrogens and progestins from oral 
contraceptives inadvertently during early pregnancy. (See <span class="Bold"><a href="#section-9">PRECAUTIONS</a></span>.)</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#section-3">BOXED 
WARNINGS</a></span>.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span><p>Estrogen with progestin therapy has been associated with an 
increased risk of cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, as well as <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> or VTE). Should any of these occur or be suspected, estrogen 
with progestin should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and 
<span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<a href="http://"></a><p><span>Coronary Heart Disease and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>:</span> In the Women's Health Initiative (WHI) study, an increase in the 
number of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> was observed in women receiving CE compared to placebo.</p>
<p>In the CE/MPA substudy of WHI, an increased risk of coronary heart disease 
(CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was 
observed in women receiving CE/MPA compared to women receiving placebo (37 vs. 
30 per 10,000 women-years). The increase in risk was observed in year one and 
persisted. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, 
Clinical Studies</a></span>.)</p>
<p>In the same substudy of WHI, an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed in 
women receiving CE/MPA compared to women receiving placebo (29 vs. 21 per 10,000 
women-years). The increase in risk was observed after the first year and 
persisted. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, 
Clinical Studies</a></span>.)</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 
66.7Â years) a controlled clinical trial of secondary prevention of 
cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS) 
treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular 
benefit. During an average follow-up of 4.1Â years, treatment with CE/MPA did not 
reduce the overall rate of CHD events in postmenopausal women with established 
coronary heart disease. There were more CHD events in the CE/MPA-treated group 
than in the placebo group in yearÂ 1, but not during the subsequent years. Two 
thousand three hundred and twenty one women from the original HERS trial agreed 
to participate in an open-label extension of HERS, HERS II. Average follow-up in 
HERS II was an additional 2.7Â years, for a total of 6.8Â years overall. Rates of 
CHD events were comparable among women in the CE/MPA group and the placebo group 
in HERS, HERS II, and overall.</p>
<p>Large doses of estrogen (5Â mg conjugated estrogens per day), comparable to 
those used to treat cancer of the prostate and breast, have been shown in a 
large prospective clinical trial in men to increase the risks of nonfatal 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
<a href="http://"></a><p><span><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> (VTE.):</span> 
In the Women's Health Initiative (WHI) study, an increase in VTE was observed in 
women receiving CE compared to placebo.</p>
<p>In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep 
<span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, was observed in women receiving CE/MPA 
compared to women receiving placebo. The rate of VTE was 34 per 10,000 
women-years in the CE/MPA group compared to 16 per 10,000 women-years in the 
placebo group. The increase in VTE risk was observed during the first year and 
persisted. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, 
Clinical Studies</a></span>.)</p>
<p>If feasible, estrogens with progestins should be discontinued at least 4 to 6 
weeks before surgery of the type associated with an increased risk of 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
<a href="http://"></a><a href="http://"></a>Breast Cancer<p>The use of estrogens and progestins by postmenopausal women has 
been reported to increase the risk of breast cancer. The most important 
randomized clinical trial providing information about this issue is the Women's 
Health Initiative (WHI) substudy of CE/MPA. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, Clinical Studies</a></span>.) The 
results from observational studies are generally consistent with those of the 
WHI clinical trial and report no significant variation in the risk of breast 
cancer among different estrogens or progestins, doses, or routes of 
administration.</p>
<p>The CE/MPA substudy of WHI reported an increased risk of breast cancer in 
women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies 
have also reported an increased risk for estrogen/progestin combination therapy, 
and a smaller increased risk for estrogen alone therapy, after several years of 
use. In the WHI trial and from observational studies, the excess risk increased 
with duration of use. From observational studies, the risk appeared to return to 
baseline in about five years after stopping treatment. In addition, 
observational studies suggest that the risk of breast cancer was greater, and 
became apparent earlier, with estrogen/progestin combination therapy as compared 
to estrogen alone therapy.</p>
<p>In the CE/MPA substudy, 26% of the women reported prior use of estrogen alone 
and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 
5.6 years during the clinical trial, the overall relative risk of invasive 
breast cancer was 1.24 (95% confidence interval 1.01-1.54), and the overall 
absolute risk was 41 vs. 33 cases per 10,000 women-years, for CE/MPA compared 
with placebo. Among women who reported prior use of hormone therapy, the 
relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 
vs. 25 cases per 10,000 women-years, for CE/MPA compared with placebo. Among 
women who reported no prior use of hormone therapy, the relative risk of 
invasive breast cancer was 1.09, and the absolute risk was 40 vs. 36 cases per 
10,000 women-years for CE/MPA compared with placebo. In the same substudy, 
invasive breast cancers were larger and diagnosed at a more advanced stage in 
the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare 
with no apparent difference between the two groups. Other prognostic factors 
such as histologic subtype, grade and hormone receptor status did not differ 
between the groups.</p>
<p>The use of estrogen plus progestin has been reported to result in an increase 
in abnormal mammograms requiring further evaluation. All women should receive 
yearly breast examinations by a healthcare provider and perform monthly breast 
self-examinations. In addition, mammography examinations should be scheduled 
based on patient age, risk factors, and prior mammogram results.</p>
<a href="http://"></a><a href="http://"></a>Vision Disorders<p>Discontinue medication pending examination if there is sudden 
partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or if there is a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, 
<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular 
lesions, medication should be withdrawn.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span><p>In the Women's Health Initiative Memory Study (WHIMS), 4,532 
generally healthy postmenopausal women 65 years of age and older were studied, 
of whom 35% were 70 to 74 years of age and 18% were 75 or older. After an 
average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n = 
2,229) and 21 women in the placebo group (0.9%, n = 2,303) received diagnoses of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk for CE/MPA vs. placebo was 2.05 (95% 
confidence interval 1.21 â€“ 3.48), and was similar for women with and without 
histories of menopausal hormone use before WHIMS. The absolute risk of probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA vs. placebo was 45 vs. 22 cases per 10,000 women-years, and 
the absolute excess risk for CE/MPA was 23 cases per 10,000 women-years. It is 
unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#section-5.2">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span> and <span class="Bold"><a href="#section-9.9">PRECAUTIONS, 
Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Use of estrogens with a progestin may increase the risk of breast 
cancer compared to estrogen alone.</p>
<a href="http://"></a><a href="http://"></a>Ovarian Cancer<p>The CE/MPA substudy of WHI reported that estrogen plus progestin 
increased the risk of ovarian cancer. After an average follow-up of 5.6 years, 
the relative risk for ovarian cancer for CE/MPA vs. placebo was 1.58 (95% 
confidence interval 0.77 â€“ 3.24) but was not statistically significant. The 
absolute risk for CE/MPA vs. placebo was 4.2 vs. 2.7 cases per 10,000 
women-years. In some epidemiologic studies, the use of estrogen alone, in 
particular for ten or more years, has been associated with an increased risk of 
ovarian cancer. Other epidemiologic studies have not found these 
associations.</p>
<a href="http://"></a><a href="http://"></a>General<ol>
<li>The pretreatment physical examination should include special reference to 
breast and pelvic organs, as well as Papanicolaou smear.</li>
<li>Because progesterone may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, conditions 
which might be influenced by this factor, such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, 
cardiac or renal dysfunction, require careful observation.</li>
<li>In cases of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in any cases of irregular vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, nonfunctional causes should be considered. In cases of undiagnosed 
<span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, adequate diagnostic measures are indicated.</li>
<li>Patients who have a history of clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully 
observed and the drug discontinued if the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious 
degree.</li>
<li>Further studies are needed to determine any possible influence of prolonged 
progestin therapy on pituitary, ovarian, adrenal, hepatic or uterine 
functions.</li>
<li>Although concomitant use of conjugated estrogens and PROMETRIUM Capsules did 
not result in a decrease in glucose tolerance, diabetic patients should be 
carefully observed while receiving estrogen-progestin therapy.</li>
<li>The pathologist should be advised of progestin therapy when relevant 
specimens are submitted.</li>
<li>Because of the occurrence of thrombotic disorders (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, 
<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorders</span>) in 
patients taking estrogen-progestin combinations, the healthcare provider should 
be alert to the earliest manifestation of these disorders.</li>
<li>Transient <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may occur in some patients. Use caution when driving a 
motor vehicle or operating machinery. A small percentage of women may experience 
the following symptoms upon initial therapy: extreme <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and/or 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, difficulty walking, loss of 
consciousness, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span>, and shortness 
of breath. For these women, consultation with their healthcare provider 
regarding their treatment is advised. Bedtime dosing may alleviate these 
symptoms.</li>
<li>Rare instances of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> of possible orthostatic origin 
have been observed in patients taking PROMETRIUM Capsules.</li>
</ol>
<a href="http://"></a><a href="http://"></a>Information for the Patient<p>See accompanying Patient Insert.</p>
<a href="http://"></a><p><span class="Bold">General: This product contains peanut oil and 
should not be used if you are allergic to peanuts.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<a href="http://"></a>Drug/Laboratory Test Interactions<p class="First">The following laboratory results may be altered by the use of 
estrogen-progestin combination drugs:</p>
<ul>
<li>Increased sulfobromophthalein retention and other hepatic function 
tests.</li>
<li>Coagulation tests: increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> factors VII, VIII, IX and X.</li>
<li>Metyrapone test.</li>
<li>Pregnanediol determination.</li>
<li>Thyroid function: increase in PBI, and butanol extractable protein bound 
iodine and decrease in T3 uptake values.</li>
</ul>
<p>Fasting and 2-hour plasma insulin and glucose levels following an oral 
glucose tolerance test (OGTT) and fibrinogen levels were measured in patients 
receiving PROMETRIUM Capsules at a dose of 200 mg/day for 12 days per 28-day 
cycle in combination with conjugated estrogens 0.625 mg/day (n=120). <a href="#t7">Table 7</a> summarizes these data. Plasma insulin levels 2Â hours 
post-OGTT were decreased from baseline. The fasting plasma glucose and fasting 
plasma insulin levels were also decreased from baseline. Glucose levels 2 hours 
post-OGTT were increased slightly. There was no effect on fibrinogen levels.</p>
<p>For information on changes in lipid profile, see the <span class="Bold"><a href="#t5">Clinical Studies subsection, TableÂ 5</a></span>.</p>
<a href="http://"></a><a name="i2f00e73f-340f-4630-876b-196edadf1560"></a><table width="100%">
<caption><span>TABLE 7 Mean Changes from Baseline in Insulin and Glucose Levels After 
36 Months of Treatment</span></caption>
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<col align="left" width="12%">
<thead>
<tr class="First">
<td align="left"><span class="Bold">Parameter</span></td>
<td align="left">
<span class="Bold">Treatment Group</span><br><span class="Bold">Mean (Mean % 
Change)</span>
</td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left">
<span class="Bold">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg 
(cyclical)</span><span class="Sup">a</span>
</td>
<td align="left"><span class="Bold">Conjugated Estrogens 0.625 mg (only)</span></td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">n= 
173 to 176<span class="Sup">b</span></span></td>
<td align="left"><span class="Bold">n=170 to 172<span class="Sup">b</span></span></td>
<td align="left"><span class="Bold">n=171</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">Mean<br>Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
<td align="left"><span class="Bold">Mean 
Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
<td align="left"><span class="Bold">Mean 
Change</span></td>
<td align="left"><span class="Bold">Mean % 
Change</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">OGTT<br>Â Â Â Insulin<br>Â Â Â  (pmol/L)</td>
<td align="left">
<br>fasting<br>2 hours</td>
<td align="left">
<br>-2.2<br>-45.2</td>
<td align="left">
<br>-6.2<br>-14.5</td>
<td align="left">
<br>-1.1<br>-23.9</td>
<td align="left">
<br>-3.2<br>-7.9</td>
<td align="left">
<br>5.1<br>-29.7</td>
<td align="left">
<br>14.2<br>-9.1</td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left">Â </td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
</tr>
<tr>
<td align="left">Â Â Â Glucose<br>Â Â Â  (mg/dL)</td>
<td align="left">fasting<br>2 hours</td>
<td align="left">-3.0<br>3.6</td>
<td align="left">-2.9<br>5.2</td>
<td align="left">-2.7<br>5.0</td>
<td align="left">-2.7<br>7.8</td>
<td align="left">-1.0<br>2.1</td>
<td align="left">-0.9<br>3.9</td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left">Â </td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
</tr>
</tbody>
</table>
<span class="Sup">a</span> There are no significant changes (p less than 0.05) from conjugated estrogens values.<br><span class="Sup">b</span> Number of subjects (n) varies by parameter.<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p class="First">Progesterone has not been tested for carcinogenicity in animals 
by the oral route of administration. When implanted into female mice, 
progesterone produced mammary carcinomas, ovarian granulosa cell tumors and 
endometrial stromal <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>. In dogs, long-term intramuscular injections 
produced nodular <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign and malignant mammary tumors. 
Subcutaneous or intramuscular injections of progesterone decreased the latency 
period and increased the incidence of mammary tumors in rats previously treated 
with a chemical carcinogen.</p>
<p>Progesterone did not show evidence of genotoxicity in <span class="Italics">in 
vitro</span> studies for point mutations or for chromosomal damage. <span class="Italics">In vivo</span> studies for chromosome damage have yielded positive 
results in mice at oral doses of 1000 mg/kg and 2000 mg/kg. Exogenously 
administered progesterone has been shown to inhibit ovulation in a number of 
species and it is expected that high doses given for an extended duration would 
impair fertility until the cessation of treatment.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy Category B<p>Reproductive studies have been performed in mice at doses up to 9 
times the human oral dose, in rats at doses up to 44 times the human oral dose, 
in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an 
implanted device, in guinea pigs at doses of approximately one-half the human 
oral dose and in rhesus monkeys at doses approximately the human dose, all based 
on body surface area, and have revealed little or no evidence of impaired 
fertility or harm to the fetus due to progesterone.</p>
<p>Rare cases of congenital anomalies including <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span>, 
hypospadia, <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span>, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>, and other 
congenital heart defects have been reported in the infants of women using 
progesterone, including PROMETRIUM Capsules, in early pregnancy. Definitive 
causality has not been established. Rare instances of <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and 
<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> have been reported in pregnant women prescribed PROMETRIUM 
Capsules for unapproved indications including the prevention of such outcomes. 
Studies in humans cannot rule out the possibility of harm. Therefore, PROMETRIUM 
Capsules should be used during pregnancy only if indicated. (See <span class="Bold"><a href="#section-7">CONTRAINDICATIONS</a></span>.)</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>The administration of any drug to nursing mothers should be done 
only when clearly necessary since many drugs are excreted in human milk. 
Detectable amounts of progestin have been identified in the milk of nursing 
mothers receiving progestins. Caution should be exercised when PROMETRIUM 
Capsules are administered to a nursing woman.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>PROMETRIUM Capsules are not indicated in children.</p>
<a href="http://"></a><a href="http://"></a>Geriatric Use<p>Clinical studies of PROMETRIUM Capsules did not include 
sufficient numbers of subjects aged 65 and over to determine whether they 
respond differently from younger subjects. Other reported clinical experience 
has not identified differences in responses between the elderly and younger 
patients. In general, dose selection for an elderly patient should be cautious, 
usually starting at the low end of the dosing range, reflecting the greater 
frequency of decreased hepatic, renal, or cardiac function, and of concomitant 
disease or other drug therapy.</p>
<p>In the Women's Health Initiative Memory Study, including 4,532 women 65 years 
of age and older, followed for an average of 4 years, 82% (n = 3,729) were 65 to 
74 while 18% (n = 803) were 75 and over. Most women (80%) had no prior hormone 
therapy use. Women treated with conjugated estrogens plus medroxyprogesterone 
acetate were reported to have a two-fold increase in the risk of developing 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alzheimer's disease was the most common classification of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the conjugated estrogens plus medroxyprogesterone 
acetate group and the placebo group. Ninety percent of the cases of probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in the 54% of women that were older than 70. (See <span class="Bold"><a href="#section-8.4">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#section-3">BOXED WARNINGS</a>, <a href="#section-8">WARNINGS</a></span>, and <span class="Bold"><a href="#section-9">PRECAUTIONS</a></span>.</p>
<p>Because clinical trials are conducted under widely varying conditions, 
adverse reaction rates observed in the clinical trials of a drug cannot be 
directly compared to rates in the clinical trials of another drug and may not 
reflect the rates observed in practice. The adverse reaction information from 
clinical trials does, however, provide a basis for identifying the adverse 
events that appear to be related to drug use and for approximate rates.</p>
<a href="http://"></a><p><span class="Bold">Endometrial Protection:</span><a href="#t8">Table 8</a> lists adverse experiences which were reported in greater than or equal to 2% of 
patients (regardless of relationship to treatment) who received cyclic 
PROMETRIUM Capsules, 200 mg daily (12 days per calendar month cycle) with daily 
0.625 mg conjugated estrogen, in a multicenter, randomized, double-blind, 
placebo-controlled clinical trial in 875 postmenopausal women.</p>
<a href="http://"></a><a name="i1be3ac73-2093-42e8-8898-b712679b795c"></a><table width="100%">
<caption><span>TABLE 8 Adverse Experiences (â‰¥2%) Reported in an 875 Patient 
Placebo-Controlled Trial in Postmenopausal Women Over a 3-Year Period 
[Percentage (%) of Patients Reporting]</span></caption>
<col align="left" width="34%">
<col align="left" width="30%">
<col align="left" width="22%">
<col align="left" width="12%">
<thead>
<tr class="First">
<td align="left"><br></td>
<td align="left"><span class="Bold">PROMETRIUM 
Capsules 200Â mg with Conjugated Estrogens 0.625 mg</span></td>
<td align="left"><span class="Bold">Conjugated 
Estrogens 0.625 mg<br>(only)</span></td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">(n=178)</span></td>
<td align="left"><span class="Bold">(n=175)</span></td>
<td align="left"><span class="Bold">(n=174)</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">31</td>
<td align="left">30</td>
<td align="left">27</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast Tenderness</span></td>
<td align="left">27</td>
<td align="left">16</td>
<td align="left">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span></td>
<td align="left">20</td>
<td align="left">22</td>
<td align="left">29</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="left">19</td>
<td align="left">18</td>
<td align="left">12</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left">15</td>
<td align="left">5</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">Abdominal Bloating</span></td>
<td align="left">12</td>
<td align="left">10</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flashes</span></td>
<td align="left">11</td>
<td align="left">14</td>
<td align="left">35</td>
</tr>
<tr>
<td align="left">Urinary Problems</td>
<td align="left">11</td>
<td align="left">10</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="left">10</td>
<td align="left">13</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal Discharge</span></td>
<td align="left">10</td>
<td align="left">10</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> / <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left">8</td>
<td align="left">6</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Worry</span></td>
<td align="left">8</td>
<td align="left">5</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="left">7</td>
<td align="left">4</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">7</td>
<td align="left">7</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night Sweats</span></td>
<td align="left">7</td>
<td align="left">5</td>
<td align="left">17</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></td>
<td align="left">6</td>
<td align="left">6</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">Swelling of Hands</span> and 
Feet</td>
<td align="left">6</td>
<td align="left">9</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">Vaginal Dryness</span></td>
<td align="left">6</td>
<td align="left">8</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="left">3</td>
<td align="left">3</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">Breast Carcinoma</td>
<td align="left">2</td>
<td align="left">less than 1</td>
<td align="left">less than 1</td>
</tr>
<tr>
<td align="left">Breast Excisional 
Biopsy</td>
<td align="left">2</td>
<td align="left">1</td>
<td align="left">less than 1</td>
</tr>
<tr class="Last">
<td align="left">Cholecystectomy</td>
<td align="left">2</td>
<td align="left">less than 1</td>
<td align="left">less than 1</td>
</tr>
</tbody>
</table>
<a href="http://"></a><p><span class="Bold">Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>:</span><a href="#t9">Table 
9</a> lists adverse experiences which were reported in greater than or equal to 5% of patients receiving 
PROMETRIUM Capsules, 400 mg/day, in a multicenter, randomized, double-blind, 
placebo-controlled clinical trial in estrogen-primed (6 weeks) postmenopausal 
women receiving conjugated estrogens 0.625 mg/day and cyclic (10 days per 
calendar month cycle) PROMETRIUM Capsules at a dose of 400 mg/day, for three 
cycles.</p>
<a href="http://"></a><a name="i92398597-5483-4db3-8e5d-459d2d237a3b"></a><table width="100%">
<caption><span>TABLE 9 Adverse Experiences (â‰¥5%) Reported in Patients Using 400 mg/day 
in a Placebo-Controlled Trial in Estrogen-Primed Postmenopausal Women</span></caption>
<col align="left" width="44%">
<col align="left" width="32%">
<col align="left" width="22%">
<thead>
<tr class="First">
<td align="left"><span class="Bold">Adverse Experience</span></td>
<td align="left">
<span class="Bold">PROMETRIUM</span><br><span class="Bold">Capsules 400 mg</span>
</td>
<td align="left"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><span class="Bold">n=25</span></td>
<td align="left"><span class="Bold">n=24</span></td>
</tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><span class="Bold">Percentage (%) of Patients</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left">8</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">16</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left">24</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Â Â Â Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span> 
(<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span>)</td>
<td align="left">8</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> 
(Cramping)</td>
<td align="left">20</td>
<td align="left">13</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">8</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">8</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="left">8</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">Â Â Â Musculoskeletal 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="left">12</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td align="left">8</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></td>
<td align="left">16</td>
<td align="left">8</td>
</tr>
<tr>
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection Viral</span></td>
<td align="left">12</td>
<td align="left">0</td>
</tr>
<tr class="Last">
<td align="left">Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="left">8</td>
<td align="left">0</td>
</tr>
</tbody>
</table>
<p>The most common adverse experiences reported in greater than or equal to 5% of patients in all 
PROMETRIUM Capsules dosage groups studied in this trial (100 mg/day to 400 
mg/day) were: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (16%), <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> (11%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (10%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> 
(10%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (9%), <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> (7%), abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> (6%), 
<span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span> (6%), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> (6%), <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (5%), and upper 
<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span> (5%).</p>
<p>Other adverse events reported in less than 5% of patients taking PROMETRIUM 
Capsules include:</p>
<p><span>Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, 
<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span></p>
<p><span>Blood and Lymphatic System:</span> 
<span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p>
<p><span><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, 
<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span></p>
<p><span>Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span></p>
<p><span><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span></p>
<p><span>Gastrointestinal System Disorders:</span> 
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, hemorrhagic rectum, hiatus 
<span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span>General Disorders:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p>
<p><span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span> <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, herpes simplex</p>
<p><span>Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural 
Complications:</span> <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span></p>
<p><span>Musculoskeletal and Connective Tissue 
Disorders:</span> <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">muscle disorder</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, 
impaired concentration, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, speech disorder</p>
<p><span>Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span></p>
<p><span>Renal and Urinary Disorders:</span> urinary tract 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p>
<p><span>Reproductive System Disorders:</span> fungal 
<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroid</span>, <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span></p>
<p><span><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, 
<span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></p>
<p><span>Skin and Subcutaneous Tissue Disorders:</span> 
<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">verruca</span>, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> debridement</p>
<p><span><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p>The following adverse experiences have been reported with PROMETRIUM Capsules 
in other U.S. clinical trials: increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>, 
<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>.</p>
<p>In addition to the adverse events observed in clinical trials, the following 
spontaneous adverse events have been reported during the marketing of PROMETRIUM 
Capsules.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold">Congenital, Familial, and Genetic Disorders:</span> cleft 
lip, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, congenital heart disease, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>, 
<span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span></p>
<p><span class="Bold">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, visual 
disturbance</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, 
<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span></p>
<p><span class="Bold">General Disorders and Administration Site Conditions:</span> 
<span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, difficulty walking, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span></p>
<p><span class="Bold">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, cholestatic 
<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, increased 
liver function tests</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Bold">Investigations:</span> <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, 
<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, gamma-glutamyl transferase increased, 
hepatic enzyme increased, blood glucose increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, weight 
increased</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, muscle 
<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramp</span></p>
<p><span class="Bold">Neoplasms Benign, Malignant, and Unspecified:</span> 
endometrial carcinoma</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, depressed 
consciousness, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sedation, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, 
<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (with and without <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>), transient ischemic attack</p>
<p><span class="Bold">Pregnancy, Puerperium, and Perinatal Conditions:</span> 
intra-uterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span></p>
<p><span class="Bold">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, 
<span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>,</p>
<p><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> 
<span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span></p>
<p><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> 
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, 
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p>The following additional adverse experiences have been observed in women 
taking estrogen and/or progestins in general: breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, spotting, 
change in menstrual flow, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, changes in weight (increase or decrease), 
changes in the cervical squamo-columnar junction and cervical secretions, 
<span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (allergic) 
with and without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span>, that may persist when drug is 
discontinued, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, increase in size of uterine leiomyomata, ovarian 
cancer, <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, endometrial cancer, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, nipple 
discharge, increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, enlargement of hepatic 
<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, hemorrhagic 
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, intolerance to contact lenses, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, reduced carbohydrate 
tolerance, aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, changes in libido, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, 
<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, increased triglycerides.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No studies on overdosage have been conducted in humans. In the case of 
overdosage, PROMETRIUM Capsules should be discontinued and the patient should be 
treated symptomatically.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Prevention of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span>:</span> 
PROMETRIUM Capsules should be given as a single daily dose at bedtime, 200 mg 
orally for 12 days sequentially per 28-day cycle, to postmenopausal women with a 
uterus who are receiving daily conjugated estrogens tablets.</p>
<a href="http://"></a><p><span class="Bold">Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>:</span> PROMETRIUM Capsules 
may be given as a single daily dose of 400Â mg at bedtime for 10 days.</p>
<p>Some women may experience difficulty swallowing PROMETRIUM Capsules. For 
these women, PROMETRIUM Capsules should be taken with a glass of water while in 
the standing position.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PROMETRIUMÂ® (progesterone, USP) Capsules 100 mg are round, 
peach-colored capsules branded with black imprint â€œSV.â€?</p>
<a name="id33413c4-76ac-46fb-8621-be53a8e28667"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>NDC 54868-4250-1<br>
</td>
<td>Bottles of 10<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-4250-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
</tbody></table>
<p>PROMETRIUMÂ® (progesterone, USP) Capsules 200 mg are oval, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow-colored 
capsules branded with black imprint â€œSV2.â€?</p>
<a name="i07e87c8c-321a-47d2-8306-662eddd65016"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>NDC 54868-4230-2<br>
</td>
<td>Bottles of 5<br>
</td>
</tr>
<tr>
<td>NDC 54868-4230-1<br>
</td>
<td>Bottles of 10<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-4230-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C 
(59Â° to 86Â°F) [See USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Protect from excessive moisture.</span></p>
<p><span class="Bold">Dispense in tight, light-resistant container as defined in 
USP/NF, accompanied by a Patient Insert.</span></p>
<p><span class="Bold">Keep out of reach of children.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Manufactured by:<br></span>Catalent Pharma Solutions<br>St. 
Petersburg, FL 33716</p>
<p><span class="Bold">Marketed by:<br></span>Solvay Pharmaceuticals, 
Inc.<br>Marietta, GA 30062</p>
<p>Â© 2008 Solvay Pharmaceuticals, Inc.<br>All rights reserved.</p>
<p>500032 Rev Jan 2008</p>
<p>500033 Rev Jan 2008</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PATIENT INFORMATION<br>(Updated 02 Jan 
2008)</span></p>
<p><span class="Bold">PROMETRIUMÂ® (progesterone, USP)<br>Capsules 100 
mg<br>Capsules 200 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Read this PATIENT INFORMATION before you start taking PROMETRIUMÂ® Capsules 
and read what you get each time you refill PROMETRIUM Capsules, because there 
may be new information. This information does not take the place of talking to 
your healthcare provider about your medical condition or your treatment.</p>
<a name="ieb19f2d9-216b-4096-8dbc-273845c9ea40"></a><table width="100%">
<col align="left" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="left">
<span class="Bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT PROMETRIUM 
CAPSULES (A Progesterone Hormone)?</span><br><ul>
<li>Progesterone with or without estrogens should not be used to prevent heart 
attacks or heart disease.</li>
<li>Using estrogens with or without progestins may increase your chances of 
getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots. Using estrogens 
with progestins may increase your risk of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. You and your healthcare 
provider should talk regularly about whether you still need treatment with 
PROMETRIUM Capsules.</li>
</ul>
</td></tr></tbody>
</table>
<p><span class="Bold">THIS PRODUCT CONTAINS PEANUT OIL AND SHOULD NOT BE USED IF 
YOU ARE ALLERGIC TO PEANUTS.</span></p>
<p><span class="Bold">WHAT IS PROMETRIUM CAPSULES?</span></p>
<p>PROMETRIUM Capsules contain the female hormone called progesterone.</p>
<p><span class="Bold">What is PROMETRIUM Capsules used for?</span></p>
<p><span>Treatment of Menstrual Irregularities</span></p>
<p>PROMETRIUM Capsules are used for the treatment of secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> 
(absence of menstrual periods in women who have previously had a menstrual 
period) due to a decrease in progesterone. When you do not produce enough 
progesterone, menstrual irregularities can occur. If your healthcare provider 
has determined your body does not produce enough progesterone on its own, 
PROMETRIUM Capsules may be prescribed to provide the progesterone you need.</p>
<p><span>Protection of the Endometrium (Lining of the 
Uterus)</span></p>
<p>PROMETRIUM Capsules are used in combination with estrogen-containing 
medications in postmenopausal women with a uterus. Taking estrogens alone 
increases the chance of developing a condition called <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, 
that may lead to cancer of the lining of the uterus. In general, the addition of 
a progestin is recommended for women with a uterus to reduce the chance of 
getting cancer of the uterus.</p>
<p><span class="Bold">Who should not take PROMETRIUM Capsules?</span></p>
<p>Do not start taking PROMETRIUM Capsules if you:</p>
<ul>
<li><span class="Bold">are allergic to peanuts.</span></li>
<li>
<span class="Bold">are allergic to progesterone, progesterone-like drugs, or 
any of the inactive ingredients in the capsules.</span> See the end of this 
leaflet for a list of ingredients in PROMETRIUM Capsules.</li>
<li><span class="Bold">are pregnant or suspect that you are pregnant.</span></li>
<li><span class="Bold">have or have had blood clots in the legs, lungs, eyes, 
brain, or elsewhere.</span></li>
<li><span class="Bold">have liver disease.</span></li>
<li><span class="Bold">have known or suspected cancer of the breast or 
reproductive organs.</span></li>
<li><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina which has not been 
evaluated by your healthcare provider.</span></li>
<li><span class="Bold">have a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and your healthcare provider suspects 
some tissue is still in the uterus.</span></li>
<li><span class="Bold">are nursing.</span></li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>
<span class="Bold">if you are breastfeeding.</span> The hormones in PROMETRIUM 
Capsules can pass into your milk.</li>
<li>
<span class="Bold">about all of your medical problems.</span> Your healthcare 
provider may need to check you more carefully if you have certain conditions, 
such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, 
<span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have 
high calcium levels in your blood.</li>
<li>
<span class="Bold">about all the medicines you take.</span> This includes 
prescription and nonprescription medicines, vitamins, and herbal supplements. 
Some medicines may affect how PROMETRIUM Capsules works. PROMETRIUM Capsules may 
also affect how your other medicines work.</li>
</ul>
<p><span class="Bold">How should I take PROMETRIUM Capsules?</span></p>
<ol>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span>: Postmenopausal women with a uterus 
who are taking estrogens should take a single daily dose of 200 mg PROMETRIUM 
Capsules at bedtime for 12 continuous days per 28-day cycle.</li>
<li>Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>: PROMETRIUM Capsules may be given as a single daily 
dose of 400Â mg at bedtime for 10 days.</li>
<li><span class="Bold">PROMETRIUM Capsules are to be taken at bedtime as some 
women become very drowsy* and/or dizzy* after taking PROMETRIUM Capsules. In a 
small percentage of these women, these effects may be increased including 
<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, difficulty speaking, difficulty walking, and <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>. 
If you experience these symptoms, discuss them with your healthcare provider 
immediately. Taking PROMETRIUM Capsules at bedtime may minimize the impact of 
these symptoms.</span></li>
</ol>
<p>* Use caution when driving a motor vehicle or operating machinery as 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur.</p>
<p>If you experience difficulty in swallowing PROMETRIUM Capsules, it is 
recommended that you take your daily dose at bedtime with a glass of water while 
in the standing position.</p>
<p><span class="Bold">What are the risks associated with PROMETRIUM 
Capsules?</span></p>
<ul>
<li>
<span>Risk to the Fetus:</span> Rare cases of cleft 
palate, <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span>, hypospadia, and congenital heart defects have been reported 
in the infants of women using progesterone, including PROMETRIUM Capsules during 
early pregnancy. Although it is not clear that these events were drug related, 
you should check with your healthcare provider about the risks to your unborn 
child of any medication taken during pregnancy.</li>
<li>
<span>Abnormal Blood Clotting:</span> Use of 
progestational drugs has been associated with changes in the blood-clotting 
system. These changes allow the blood to clot more easily, possibly allowing 
clots to form in the bloodstream. If blood clots do form in your bloodstream, 
they can cut off the blood supply to vital organs, causing serious problems. 
These problems may include a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (by cutting off blood to part of the brain), 
a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> (by cutting off blood to part of the heart), a <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> 
(by cutting off blood to part of the lungs), visual loss or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> (by 
cutting off blood vessels in the eye), or other problems. Any of these 
conditions may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious long-term <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Call your healthcare 
provider immediately if you suspect you have any of these conditions. He or she 
may advise you to stop using this drug.</li>
<li>
<span>Eye Abnormalities:</span> Discontinue medication 
and call your healthcare provider immediately if you experience sudden partial 
or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or sudden onset of bulging eyes, 
<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</li>
</ul>
<p><span class="Bold">What are the possible side effects of PROMETRIUM 
Capsules?</span></p>
<p>Consult your healthcare provider if you experience any of the side effects 
mentioned below or other side effects.</p>
<p>SIDE EFFECTS REPORTED IN STUDIES OF PATIENTS AT DOSES OF 100 MG/DAY TO 400 
MG/DAY:</p>
<p><span>Blood and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the 
lymph nodes<br><span>Cardiovascular System:</span> high 
blood pressure, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, pounding or racing of the heart<br><span>Digestive System:</span> <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, 
<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><span>General Disorders:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (cramping), back 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, intestinal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, 
<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the legs and arms<br><span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, fungal <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the vagina, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, 
<span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span><br><span>Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, 
muscle or <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span><br><span>Nervous/Psychiatric System:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
decreased concentration, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>*, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>*, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, mood 
swings, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span><br><span>Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, fluid in sinus 
cavities, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, fluid in the lungs<br><span>Reproductive System:</span> <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, 
<span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span>, <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine fibroid</span><br><span>Skin</span>: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span><br><span>Eyes:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span><br><span>Kidney and Urinary System:</span> urinary problems</p>
<p>* Use caution when driving a motor vehicle or operating machinery as 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur.</p>
<p>During the marketing of PROMETRIUM Capsules, other adverse events have been 
reported, including reversible cases of liver problems, particularly in patients 
taking high doses. Additionally, rare occurrences of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> and/or low blood 
pressure have also been reported.</p>
<p><span class="Bold">These are some of the warning signs of serious side 
effects:</span></p>
<p>Be alert for unusual signs and symptoms. If any of these warning signals (or 
any other unusual symptoms) happen while you are using PROMETRIUM Capsules, call 
your healthcare provider immediately:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (Ask your healthcare provider to show you how to examine your 
breasts monthly.)</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the abdomen</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, 
heart problems, or kidney problems</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina</li>
<li>Feelings of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in the calves or chest; a sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>; or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> 
blood, indicating possible clots in the legs, heart or lungs</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, faintness, or changes in vision or 
speech; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg, indicating possible clots in the 
brain or eye</li>
</ul>
<p><span class="Bold">General information about safe and effective use of 
PROMETRIUM Capsules</span></p>
<ul>
<li>Medicines are sometimes prescribed for conditions that are not mentioned in 
patient information leaflets. Do not take PROMETRIUM Capsules for conditions for 
which it was not prescribed.</li>
<li>Your healthcare provider has prescribed this drug for you and you alone. Do 
not give PROMETRIUM Capsules to other people, even if they have the same 
symptoms you have. It may harm them.</li>
<li>PROMETRIUM Capsules should be taken as a single daily dose at bedtime. Some 
women may experience extreme <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and/or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> during initial therapy. 
In a small percentage of women, these effects may be increased including blurred 
vision, difficulty speaking, difficulty walking, and <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>. If you 
experience these symptoms, discuss them with your healthcare provider 
immediately. A single bedtime dose may reduce the impact of these symptoms.</li>
<li>Use caution when driving a motor vehicle or operating machinery as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 
or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may occur.</li>
</ul>
<p><span class="Bold">Keep PROMETRIUM Capsules out of the reach of 
children.</span></p>
<p>This leaflet provides a summary of the most important information about 
PROMETRIUM Capsules. If you would like more information, talk with your 
healthcare provider or pharmacist. You can ask for information about PROMETRIUM 
Capsules that is written for health professionals. You can get more information 
by calling the toll free number 1-800-241-1643.</p>
<p><span class="Bold">What are the ingredients in PROMETRIUM Capsules?</span></p>
<p>Active ingredient: 100 mg or 200 mg micronized progesterone</p>
<p>The inactive ingredients for PROMETRIUM Capsules 100 mg include: peanut oil 
NF, gelatin NF, glycerin USP, lecithin NF, titanium dioxide USP, D&amp;C Yellow 
No. 10, and FD&amp;C Red No. 40.</p>
<p>The inactive ingredients for PROMETRIUM Capsules 200 mg include: peanut oil 
NF, gelatin NF, glycerin USP, lecithin NF, titanium dioxide USP, D&amp;C Yellow 
No. 10, and FD&amp;C Yellow No. 6.</p>
<p><span class="Bold">HOW SUPPLIED</span></p>
<p>PROMETRIUM Capsules 100 mg are round, peach-colored capsules branded with 
black imprint â€œSV.â€?</p>
<p>PROMETRIUM Capsules 200 mg are oval, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow-colored capsules branded 
with black imprint â€œSV2.â€?</p>
<p><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C 
(59Â° to 86Â°F) [See USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Protect from excessive moisture.</span></p>
<p><span class="Bold">Manufactured by:</span><br>Catalent Pharma Solutions<br>St. 
Petersburg, FL 33716</p>
<p><span class="Bold">Marketed by:</span><br>Solvay Pharmaceuticals, 
Inc.<br>Marietta, GA 30062</p>
<p>Â© 2008 Solvay Pharmaceuticals, Inc.<br>All rights reserved.</p>
<p>500033 Rev Jan 2008</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">PROMETRIUMÂ® (progesterone, USP) Capsules</p>
<p>100 mg</p>
<div class="Figure"><img alt="image of 100 mg packaqe label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf73c385-5173-4b54-af23-069581c5d560&amp;name=100mg%20package%20label.jpg"></div>
<p><br></p>
<p>PROMETRIUMÂ® (progesterone, USP) Capsules</p>
<br><p>200 mg<br></p>
<p><img alt="image of 200 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf73c385-5173-4b54-af23-069581c5d560&amp;name=200mg%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETRIUMÂ 		
					</strong><br><span class="contentTableReg">progesterone capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4250(NDC:0032-1708)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROGESTERONE</strong> (PROGESTERONE) </td>
<td class="formItem">PROGESTERONE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEANUT OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4250-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4250-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019781</td>
<td class="formItem">03/14/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETRIUMÂ 		
					</strong><br><span class="contentTableReg">progesterone capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4230(NDC:0032-1711-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROGESTERONE</strong> (PROGESTERONE) </td>
<td class="formItem">PROGESTERONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEANUT OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SV2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4230-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4230-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4230-2</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019781</td>
<td class="formItem">11/03/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e7c2821a-12eb-4326-9b1c-ebe8f161cd3e</div>
<div>Set id: cf73c385-5173-4b54-af23-069581c5d560</div>
<div>Version: 1</div>
<div>Effective Time: 20100824</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
